Table 1.
Major clinical trials with different classes of BP lowering drugs in hypertensive population without previous history of cerebrovascular events (less 5 % of stroke victims at the baseline)
| Trial [ref] |
No of participants | Mean age (yrs) | Main drug /comparator | Average reduction in blood pressure (mm Hg) | Number of strokes | |||
|---|---|---|---|---|---|---|---|---|
| treatment | control /comparator | systolic | diastolic | treatment | Control/comparator | |||
| ABCD-2[117] | 237 | 243 | 59 | iACE/CcCB | 7.4 | 6.0 | 4 | 13 |
| ADVANCE [118] | 5569 | 5571 | 66 | any | 5.6 | 2.2 | 215 | 218 |
| Australian TTMH [119] | 1721 | 1706 | 50 | D/plac | - | 5.6 | 13 | 22 |
| BBB [120] | 1063 | 1063 | 60 | any | 8.7 | 7.1 | 8 | 11 |
| CAPPP [121] | 5492 | 5493 | 52 | iACE/plac | - | - | 193 | 149 |
| CONVINCE [81] | 8241 | 8361 | 66 | CaCB/bB + D | 0.1 | 0.7 | 133 | 118 |
| DREAM [122] | 2623 | 2646 | 55 | iACE/plac | 4.3 | 2.7 | 4 | 8 |
| EWPHE [123] | 381 | 396 | 72 | D/plac | 21 | 8 | 27 | 39 |
| FEVER [124] | 4841 | 4870 | 62 | CaCB/plac | 4.2 | 2.1 | 177 | 251 |
| HEP [125] | 408 | 459 | 69 | D + bB/plac | 11 | 18 | 18 | 38 |
| HDFP [126–128] | 5349 | 5317 | 51 | D/plac | - | 5.3 | 87 | 142 |
| HOT [129] | 12526 | 6464 | 62 | any | 2.8 | 3.0 | 200 | 94 |
| Hunan province [130] | 1040 | 1040 | 52 | CaCB/plac | 8.8 | 5.6 | 37 | 79 |
| HYVET pilot [131] | 426 | 426 | 84 | D/plac | 22 | 11 | 6 | 18 |
| 431 | 84 | iACE/plac | 23 | 11 | 12 | - | ||
| HYVET [48] | 1933 | 1912 | 84 | D/plac | 15 | 6.1 | 51 | 69 |
| LIFE [132] | 4605 | 4588 | 66 | ARB/bB | 1.1 | -0.2 | 232 | 309 |
| MRC-1[133] | 4297 | 8654 | 52 | D/plac | 13.2 | 6.1 | 18 | 109 |
| 4403 | 52 | bB/plac | 9.5 | 4.9 | 42 | - | ||
| MRC-2 [134] | 1081 | 2213 | 70 | D/plac | 16.4 | 7.0 | 45 | 134 |
| 1102 | 70 | bB/plac | 14.1 | 7.3 | 56 | - | ||
| NORDIL [108] | 2786 | 2805 | 60 | CaCB/D + bB | 3.1 | 0.2 | 200 | 236 |
| Oslo [135] | 406 | 379 | 45 | D/plac | 16.7 | 9.8 | 0 | 5 |
| PREVENDIT [136] | 431 | 433 | 51 | iACE/plac | 3.8 | 2.9 | 1 | 10 |
| SHEP pilot [137] | 443 | 108 | 72 | D/plac | 15 | 4 | 11 | 6 |
| SHEP [138] | 2306 | 2331 | 72 | D/plac | 13.0 | 4.3 | 97 | 155 |
| STOP [139] | 781 | 780 | 76 | D + bB | 8.1 | 19.5 | 28 | 49 |
| STOP - 2 [140] | 2213 | 2196 | 76 | D + bB/CaCB | 1 | 0 | 86 | 83 |
| 2213 | 2205 | D + bB/iACE | 1 | 0 | 86 | 86 | ||
| Syst-Eur [141] | 2398 | 2297 | 70 | CaCB/plac | 10 | 4.5 | 47 | 77 |
| Syst-China [142] | 1253 | 1141 | 67 | CaCB/plac | 8.3 | 3.1 | 45 | 59 |
| TOMHS [143] | 668 | 234 | 55 | any | 6.8 | 3.7 | - | - |
| UKPDS 38 [144, 145] | 758 | 390 | 56 | any | 10 | 4 | 17 | 34 |
| UKPDS 39 [145] | 400 | 358 | 56 | iACE/bB | 11 | 6 | 21 | |
| USPHS [146] | 193 | 196 | 44 | D+Res/plac | 9.8 | 18.0 | 1 | 6 |
| VA-1[147] | 73 | 70 | 51 | D+Res+Hdr/plac | 27 | 38 | 1 | 3 |
| VA-2 [148] | 186 | 194 | 51 | D+Res+Hdr/plac | 18.6 | 31.3 | 5 | 20 |
| VANHLBI [149] | 508 | 504 | 38 | D | - | 5.9 | 0 | 0 |
D- thiazide, bB - β blocker, iACE - ACE inhibitor, ARB – angiotensin II receptor antagonist, CaCB - calcium-channel blocker, Res- rauwolfia, Hdr – hydralazine, plac - placebo